THE AMERICA ONE NEWS
Jun 5, 2025  |  
0
 | Remer,MN
Sponsor:  QWIKET 
Sponsor:  QWIKET 
Sponsor:  QWIKET: Elevate your fantasy game! Interactive Sports Knowledge.
Sponsor:  QWIKET: Elevate your fantasy game! Interactive Sports Knowledge and Reasoning Support for Fantasy Sports and Betting Enthusiasts.
back  
topic
Fox Business
Fox Business
2 Oct 2023


Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.

The once-monthly injection, which will be sold under the brand name Rivfloza, is approved for use in children who are 9 years of age and older and adults with a type of primary hyperoxaluria and relatively preserved kidney function.

Novo Nordisk headquarters

A general view of the headquarters of Danish pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept. 26, 2023. (REUTERS/Tom Little/File photo / Reuters Photos)

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones.

The Danish drugmaker gained access to the therapy through its $3.3 billion buyout of Dicerna Pharmaceuticals.